Drugs & Therapy Perspectives

, Volume 17, Issue 6, pp 1–5

Ropinirole: a promising new antiparkinsonian drug

New drugs and disease management

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. 1.
    Lambert D, Waters CH. Comparative tolerability of the newer generation antiparkinsonian agents. Drugs Aging 2000 Jan; 16(1): 55–65CrossRefPubMedGoogle Scholar
  2. 2.
    Matheson AJ, Spencer CM. Ropinirole. A review of its use in the management of Parkinson’s disease. Drugs 2000 Jul; 60(1): 115–37CrossRefPubMedGoogle Scholar
  3. 3.
    Rascol A, Brooks DJ, Korczyn AD, et al. A five-year study of the incidence of dyskinesia in patients with early Parkinson’s disease who were treated with ropinirole or levodopa. N Engl J Med 2000; 342(20): 1484–91CrossRefPubMedGoogle Scholar
  4. 4.
    Korczyn AD, Brunt ER, Larsen JP, et al. A 3-year randomized trial of ropinirole and bromocriptine in early Parkinson’s disease [erratum published in Neurology 1999; 53: 1162]. Neurology 1999; 53(2): 364–70CrossRefPubMedGoogle Scholar
  5. 5.
    Ropinirole 043 Study Group. A double-blind comparative study of ropinirole vs bromocriptine in the treatment of Parkinsonian patients not optimally controlled on l-dopa. Mov Disord 1996; 11 Suppl. 1: 188Google Scholar
  6. 6.
    Brunt ER, Korczyn AD, Lieberman A, et al. The long-term efficacy of ropinirole as an adjunct to L-dopa [abstract]. Neurology 1999; 52 Suppl. 2: A408–409Google Scholar
  7. 7.
    Brooks DJ, Rakshi JS, Pavese N, et al. Relative rates of progression of early Parkinson’s diseaese patients started on either a dopamine agonist (ropinirole) or levodopa: 2-year and 5-year follow-up 18F-dopa PET findings [abstract]. Neurology 2000; 54 Suppl. 3: A113Google Scholar
  8. 8.
    Stocchi F, Destee A. Co-administration of ropinirole and domperidone during rapid dose escalation of the dopamine agonist. Parkinsonism and Related Disorders 1998; 4(4): 183–8CrossRefPubMedGoogle Scholar
  9. 9.
    Rascol O, Lees AJ, Senard JM, et al. Ropinirole in the treatment of levodopa-induced motor fluctuations in patients with Parkinson’s disease. Clin Neuropharmacol 1996 Jun; 19: 234–45CrossRefPubMedGoogle Scholar
  10. 10.
    Schrag AE, Brooks DJ, Brunt E, et al. The safety of ropinirole, a selective nonergoline dopamine agonist, in patients with Parkinson’s disease. Clin Neuropharmacol 1998 May–Jun; 21: 169–75PubMedGoogle Scholar
  11. 11.
    Hristova AH, Koller WC. Early Parkinson’s disease. What is the best approach to treatment. Drugs Aging 2000 Sep; 17(3): 165–81CrossRefPubMedGoogle Scholar
  12. 12.
    British National Formulary No. 40. London: The Pharmaceutical Press, 2000 Sep: 234-40Google Scholar
  13. 13.
    Drug Topics Red Book. Montvale (NJ): Medical Economics Company, 2000Google Scholar
  14. 14.
    Physician’s Desk Reference. 55th ed. Montvale (NJ): Medical Economics Company 2001Google Scholar

Copyright information

© Adis International Limited 2001

Personalised recommendations